Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

“Dials Could Turn” In Genzyme Deal, But Isis First Quarter is Better

This article was originally published in The Pink Sheet Daily

Executive Summary

Isis waits for $175 million license fee, as firms iron out mipomersen details.

You may also be interested in...



Genzyme/Isis’ Mipomersen Development Outlook Pricier And Riskier After FDA Weighs In

Cardiotoxicity and outcomes requirements push back NDA timeline for the novel LDL-lowering drug.

Isis: Pondering Platform Power

The January 2008 collaboration Isis forged with Genzyme was transformative for Isis and a desperately sought-after validation of the antisense field. But unlike its brethren in oligonucleotide drug development -- and most biotechs, for that matter -- Isis rejects the notion of commercializing its products. The deal sets up a paradox: Can Isis remain a platform company once investors' focus is on a product and its trajectory? In a sense, can it stay small?

Vytorin Fails To Show ENHANCEd Benefit Over Simvastatin In Plaque Reduction

Merck/Schering-Plough felt pressure to release findings earlier than its scheduled presentation at March American College of Cardiology meeting, Schering-Plough tells “The Pink Sheet” DAILY.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067750

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel